Welcome to our dedicated page for Artelo Bioscienc SEC filings (Ticker: ATLEW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for ARTELO BIOSCIENCES WTS 25 (ATLEW) provides access to regulatory documents filed by Artelo Biosciences, Inc., the Nevada corporation associated with these warrants. The company reports material events under the Securities Exchange Act of 1934, including current reports on Form 8-K that describe offerings of common stock and pre-funded warrants, as well as underwriting arrangements and over-allotment options.
In one Form 8-K, Artelo Biosciences, Inc. details an underwriting agreement with R. F. Lafferty & Co., Inc. for an underwritten offering of common stock and pre-funded warrants, the pricing of those securities, and the partial exercise of a 45-day over-allotment option. The filing notes that the offering closed and that the company delivered the securities to the underwriter, and it specifies the resulting gross and net proceeds. Disclosures like these help investors understand how the company issues equity and related instruments that form the context for ATLEW.
On this page, you can review such filings as they appear in the SEC’s EDGAR system, with AI-powered summaries that explain the key points of each report in plain language. These summaries highlight material terms in documents such as Form 8-K, making it easier to identify information about capital-raising transactions, warrant issuances, and changes in the company’s capital structure. The platform also tracks new filings as they become available, so users can see updates related to Artelo Biosciences, Inc. and securities connected to ATLEW.
Use this page to quickly navigate Artelo Biosciences, Inc.’s filings, understand the disclosures that affect its common stock and warrant instruments, and interpret complex regulatory language through AI-generated insights.
Artelo Biosciences, Inc. reconvened its Annual Meeting of Stockholders on January 30, 2026 and reported the voting results. The meeting had previously been convened on December 31, 2025 and adjourned because there were not enough shares represented to form a quorum.
Of the 2,018,746 shares of common stock outstanding as of the December 10, 2025 record date, 1,017,816 shares were represented at the reconvened meeting, or approximately 50.4% of the shares entitled to vote. Stockholders cast votes on the election of two director nominees and on two additional matters, with detailed tallies provided for each item.
Daniel S. Farb filed a Schedule 13D disclosing a 9.8% direct stake in Artelo Biosciences, Inc. (symbol ATLEW), owning 153,000 shares purchased with personal funds for approximately $850,019. Farb also acquired warrants under a June 2025 Securities Purchase Agreement: 11,299 $10 warrants and 22,598 $5.82 warrants22,595 shares; the issuer declined delivery of 3 shares and intends to pay $17.46 for those undelivered shares. Farb delivered a director nomination letter naming himself and Scott D. Pomfret and entered a Joint Filing and Solicitation Agreement with Pomfret; Pomfret granted Farb a power of attorney to assist with the proxy solicitation. The registered resale of the SPA securities was filed on Form S-1.